These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38684449)

  • 1. Prophylaxis with emicizumab in children under 12 years old with haemophilia A without inhibitors in Uruguay: National experience.
    Lemos F; Petraccia C; Fraga ML; Casuriaga AL; Lutz S; Gómez R; Giachetto G; Boggia B
    Haemophilia; 2024 Jul; 30(4):1077-1079. PubMed ID: 38684449
    [No Abstract]   [Full Text] [Related]  

  • 2. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study.
    Mancuso ME; Mahlangu J; Sidonio R; Trask P; Uguen M; Chang T; Shima M; Young G; Oldenburg J; von Mackensen S
    Haemophilia; 2020 Nov; 26(6):1009-1018. PubMed ID: 33084175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors.
    Dubé E; Merlen C; Bonnefoy A; Pilon J; Zourikian N; Gauthier J; St-Louis J; Rivard GÉ
    Haemophilia; 2023 Jan; 29(1):348-351. PubMed ID: 36315386
    [No Abstract]   [Full Text] [Related]  

  • 4. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures.
    Escobar M; Dunn A; Quon D; Trzaskoma B; Lee L; Ko RH; Carpenter SL
    Haemophilia; 2022 Jul; 28(4):e105-e108. PubMed ID: 35510949
    [No Abstract]   [Full Text] [Related]  

  • 5. Patients on emicizumab prophylaxis with previously tolerized inhibitors: Is there a risk of inhibitors recurrence?
    Hassan E; Lancashire J; Motwani J
    Haemophilia; 2022 Mar; 28(2):e36-e38. PubMed ID: 34821004
    [No Abstract]   [Full Text] [Related]  

  • 6. Paradigm shifts in haemophilia A therapy with emicizumab prophylaxis in Asia.
    Sosothikul D; Moonla C
    Ann Acad Med Singap; 2023 Nov; 52(11):556-558. PubMed ID: 38920143
    [No Abstract]   [Full Text] [Related]  

  • 7. Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapy.
    Launois A; De Raucourt E; Martin-Toutain I; Samdjee F; Le Dore S; Ferre E; Flaujac C
    Haemophilia; 2023 Jan; 29(1):374-376. PubMed ID: 36446748
    [No Abstract]   [Full Text] [Related]  

  • 8. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
    Le Quellec S
    Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring.
    Biron-Andreani C; Diaz-Cau I; Ranc A; Navarro R; Leonardi C; Dischino M; Guy R; Theron A; Garcia-Gournay C; Santagostino E; Schved JF
    Br J Haematol; 2020 May; 189(3):e100-e103. PubMed ID: 32087028
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world data on emicizumab prophylaxis in the Milan cohort.
    Arcudi S; Gualtierotti R; Marino S; Nicolò G; Biguzzi E; Ciavarella A; Boscarino M; Siboni SM; Schiavone L; Novembrino C; Valsecchi C; Peyvandi F
    Haemophilia; 2022 Sep; 28(5):e141-e144. PubMed ID: 35853212
    [No Abstract]   [Full Text] [Related]  

  • 12. Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor.
    Kharel Z; Pruthi RK; Kouides P; Reid R
    Haemophilia; 2024 May; 30(3):868-871. PubMed ID: 38650315
    [No Abstract]   [Full Text] [Related]  

  • 13. Initiation of emicizumab prophylaxis in an infant with haemophilia A and subdural haemorrhage.
    Bush KA; Lucas TL; Haley KM; Thornburg CD
    Haemophilia; 2020 Nov; 26(6):e353-e355. PubMed ID: 32892446
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of VIII inhibitors beyond 50 exposure days to rFVIII during prophylactic emicizumab therapy.
    Mitani Y; Honda M; Mizushima Y; Mori M; Fukuoka K; Oshima K; Arakawa Y; Taira K; Tanami Y; Koh K
    Haemophilia; 2023 Nov; 29(6):1653-1655. PubMed ID: 37707369
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
    Oldenburg J; Mahlangu JN; Bujan W; Trask P; Callaghan MU; Young G; Asikanius E; Peyvandi F; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Xu J; Windyga J; Shima M; von Mackensen S
    Haemophilia; 2019 Jan; 25(1):33-44. PubMed ID: 30427582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding control improves after switching to emicizumab: Real-world experience of 177 children in the PedNet registry.
    van der Zwet K; de Kovel M; Motwani J; van Geet C; Nolan B; Glosli H; Escuriola Ettingshausen C; Königs C; Kenet G; Fischer K;
    Haemophilia; 2024 May; 30(3):685-692. PubMed ID: 38578720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
    Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M
    Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
    Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
    Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.